Article content
Sanofi on Friday won expanded
US approval for its best-selling Dupixent injection to treat
an allergic inflammation of the esophagus, the US Food and
Drug Administration said.
(Reporting by Ludwig Burger; Additional reporting by Eva
Mathews; Editing by Maju Samuel)
financialpost.com